Sorin CE marks self-anchoring aortic heart valve
This article was originally published in Clinica
Executive Summary
Sorin (Milan, Italy) has CE marked its Perceval S aortic heart valve for sale in Europe. The self-anchoring biological valve is indicated for the minimally-invasive surgical replacement of the aortic valve in patients with aortic stenosis. Around 3% of 75-year-old patients have severe symptomatic aortic stenosis and if the disorder is untreated, the average survival is only two to three years. The Perceval S is made of bovine pericardium and is mounted on a super-elastic alloy frame.
You may also be interested in...
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.